| Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation K Bensaad, E Favaro, CA Lewis, B Peck, S Lord, JM Collins, KE Pinnick, ... Cell reports 9 (1), 349-365, 2014 | 635 | 2014 |
| Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019 | 469 | 2019 |
| Imaging tumour hypoxia with positron emission tomography IN Fleming, R Manavaki, PJ Blower, C West, KJ Williams, AL Harris, ... British journal of cancer 112 (2), 238-250, 2015 | 369 | 2015 |
| Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal … PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, ... JAMA oncology 7 (6), 869-877, 2021 | 128 | 2021 |
| Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer SR Lord, WC Cheng, D Liu, E Gaude, S Haider, T Metcalf, N Patel, ... Cell metabolism 28 (5), 679-688. e4, 2018 | 126 | 2018 |
| Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer M Morotti, E Bridges, A Valli, H Choudhry, H Sheldon, S Wigfield, N Gray, ... Proceedings of the National Academy of Sciences 116 (25), 12452-12461, 2019 | 122 | 2019 |
| Gene expression and hypoxia in breast cancer E Favaro, S Lord, AL Harris, FM Buffa Genome medicine 3, 1-12, 2011 | 116 | 2011 |
| Targeting OXPHOS and the electron transport chain in cancer; molecular and therapeutic implications J Greene, A Segaran, S Lord Seminars in Cancer Biology, 2022 | 87 | 2022 |
| The current status of risk-stratified breast screening AK Clift, D Dodwell, S Lord, S Petrou, SM Brady, GS Collins, ... British journal of cancer 126 (4), 533-550, 2022 | 86 | 2022 |
| A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ... Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018 | 74 | 2018 |
| BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—initial results from arm 1, d+ paclitaxel (P), and … P Schmid, SA Im, A Armstrong, YH Park, WP Chung, Z Nowecki, S Lord, ... Journal of Clinical Oncology 39 (15_suppl), 1023-1023, 2021 | 68 | 2021 |
| Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? SR Lord, AL Harris British Journal of Cancer 128 (6), 958-966, 2023 | 57 | 2023 |
| Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours GI Shapiro, R Wesolowski, C Devoe, S Lord, J Pollard, BS Hendriks, ... British journal of cancer 125 (4), 520-527, 2021 | 50 | 2021 |
| A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO) PS Hall, SR Lord, M Collinson, H Marshall, M Jones, C Lowe, H Howard, ... British journal of cancer 116 (4), 472-478, 2017 | 47 | 2017 |
| Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin SR Lord, JM Collins, WC Cheng, S Haider, S Wigfield, E Gaude, ... British journal of cancer 122 (2), 258-265, 2020 | 38 | 2020 |
| Obesity: A perfect storm for carcinogenesis BHL Harris, VM Macaulay, DA Harris, P Klenerman, F Karpe, SR Lord, ... Cancer and Metastasis Reviews 41 (3), 491-515, 2022 | 36 | 2022 |
| Radiogenomics monitoring in breast cancer identifies metabolism and immune checkpoints as early actionable mechanisms of resistance to anti-angiogenic treatment S Mehta, NP Hughes, S Li, A Jubb, R Adams, S Lord, L Koumakis, ... EBioMedicine 10, 109-116, 2016 | 33 | 2016 |
| First-in-human phase I study of MP0250, a first-in-class DARPin drug candidate targeting VEGF and HGF, in patients with advanced solid tumors RD Baird, C Linossi, M Middleton, S Lord, A Harris, J Rodón, C Zitt, ... Journal of Clinical Oncology 39 (2), 145-154, 2021 | 27 | 2021 |
| Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer ML Telli, SM Tolaney, GI Shapiro, M Middleton, SR Lord, HT Arkenau, ... NPJ Breast Cancer 8 (1), 45, 2022 | 26 | 2022 |
| Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014; 9 (1): 349–65 K Bensaad, E Favaro, CA Lewis, B Peck, S Lord, JM Collins, KE Pinnick, ... Epub 2014/09/30. https://doi. org/10.1016/j. celrep. 2014.08. 056 PMID: 25263561, 0 | 25 | |
